Annual CFI
-$25.97 M
-$88.49 M-141.53%
31 December 2023
Summary:
Enlivex Therapeutics annual cash flow from investing activities is currently -$25.97 million, with the most recent change of -$88.49 million (-141.53%) on 31 December 2023. During the last 3 years, it has fallen by -$4.99 million (-23.79%). ENLV annual CFI is now -141.53% below its all-time high of $62.52 million, reached on 31 December 2022.ENLV Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$794.00 K
-$5.89 M-115.57%
30 June 2024
Summary:
Enlivex Therapeutics quarterly cash flow from investing activities is currently -$794.00 thousand, with the most recent change of -$5.89 million (-115.57%) on 30 June 2024. Over the past year, it has dropped by -$4.74 million (-120.13%). ENLV quarterly CFI is now -101.33% below its all-time high of $59.67 million, reached on 31 March 2022.ENLV Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
$12.38 M
+$1.91 M+18.21%
30 June 2024
Summary:
Enlivex Therapeutics TTM cash flow from investing activities is currently $12.38 million, with the most recent change of +$1.91 million (+18.21%) on 30 June 2024. Over the past year, it has increased by +$45.36 million (+137.55%). ENLV TTM CFI is now -84.68% below its all-time high of $80.86 million, reached on 31 March 2022.ENLV TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENLV Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -141.5% | -120.1% | +137.6% |
| 3 y3 years | -23.8% | -105.5% | +133.0% |
| 5 y5 years | -5083.2% | +90.1% | +281.5% |
ENLV Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -141.5% | +32.4% | -101.3% | +97.9% | -84.7% | +132.2% |
| 5 y | 5 years | -141.5% | +32.4% | -101.3% | +98.7% | -84.7% | +115.8% |
| alltime | all time | -141.5% | +32.4% | -101.3% | +98.7% | -84.7% | +115.8% |
Enlivex Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$794.00 K(-115.6%) | $12.38 M(+18.2%) |
| Mar 2024 | - | $5.10 M(+23.3%) | $10.48 M(-140.3%) |
| Dec 2023 | -$25.97 M(-141.5%) | $4.13 M(+4.8%) | -$25.97 M(-21.3%) |
| Sept 2023 | - | $3.94 M(-246.0%) | -$32.98 M(-563.2%) |
| June 2023 | - | -$2.70 M(-91.4%) | $7.12 M(-125.0%) |
| Mar 2023 | - | -$31.35 M(+989.9%) | -$28.50 M(-145.6%) |
| Dec 2022 | $62.52 M(-262.8%) | -$2.88 M(-106.5%) | $62.52 M(+4.1%) |
| Sept 2022 | - | $44.04 M(-214.9%) | $60.05 M(+98.0%) |
| June 2022 | - | -$38.32 M(-164.2%) | $30.34 M(-62.5%) |
| Mar 2022 | - | $59.67 M(-1216.2%) | $80.86 M(-310.5%) |
| Dec 2021 | -$38.41 M(+83.1%) | -$5.35 M(-137.3%) | -$38.41 M(+2.4%) |
| Sept 2021 | - | $14.32 M(+17.4%) | -$37.50 M(-33.3%) |
| June 2021 | - | $12.20 M(-120.5%) | -$56.20 M(-28.4%) |
| Mar 2021 | - | -$59.59 M(+1242.4%) | -$78.53 M(+274.3%) |
| Dec 2020 | -$20.98 M(+229.9%) | -$4.44 M(+1.5%) | -$20.98 M(+28.5%) |
| Sept 2020 | - | -$4.37 M(-56.8%) | -$16.32 M(-18.1%) |
| June 2020 | - | -$10.13 M(+396.7%) | -$19.94 M(+102.1%) |
| Mar 2020 | - | -$2.04 M(-1044.0%) | -$9.86 M(+55.1%) |
| Dec 2019 | -$6.36 M(+1169.3%) | $216.00 K(-102.7%) | -$6.36 M(-6.8%) |
| Sept 2019 | - | -$7.99 M(>+9900.0%) | -$6.82 M(-724.8%) |
| June 2019 | - | -$54.00 K(-103.7%) | $1.09 M(-1.1%) |
| Mar 2019 | - | $1.47 M(-691.1%) | $1.10 M(-320.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$501.00 K(+285.4%) | -$248.00 K(+244.4%) | -$501.00 K(-85.2%) |
| Sept 2018 | - | -$72.00 K(+71.4%) | -$3.39 M(+2.5%) |
| June 2018 | - | -$42.00 K(-69.8%) | -$3.31 M(+1139.3%) |
| Mar 2018 | - | -$139.00 K(-95.6%) | -$267.00 K(+105.4%) |
| Dec 2017 | -$130.00 K(-101.4%) | -$3.14 M(<-9900.0%) | -$130.00 K(-101.9%) |
| Sept 2017 | - | $10.00 K(-99.7%) | $6.93 M(-0.8%) |
| June 2017 | - | $3.00 M(<-9900.0%) | $6.99 M(-22.2%) |
| Mar 2017 | - | -$2000.00(-100.1%) | $8.99 M(+0.1%) |
| Dec 2016 | $8.98 M(-9.7%) | $3.92 M(+5585.5%) | $8.98 M(-18.7%) |
| Sept 2016 | - | $69.00 K(-98.6%) | $11.04 M(+10.8%) |
| June 2016 | - | $5.00 M(<-9900.0%) | $9.96 M(+0.0%) |
| Mar 2016 | - | -$8000.00(-100.1%) | $9.96 M(+0.1%) |
| Dec 2015 | $9.95 M(-145.1%) | $5.98 M(-692.4%) | $9.95 M(-155.2%) |
| Sept 2015 | - | -$1.01 M(-120.2%) | -$18.04 M(+5.8%) |
| June 2015 | - | $5.00 M(<-9900.0%) | -$17.05 M(-22.8%) |
| Mar 2015 | - | -$17.00 K(-99.9%) | -$22.08 M(+0.1%) |
| Dec 2014 | -$22.06 M(>+9900.0%) | -$22.01 M(>+9900.0%) | -$22.06 M(>+9900.0%) |
| Sept 2014 | - | -$27.00 K(0.0%) | -$56.00 K(+93.1%) |
| June 2014 | - | -$27.00 K(+1250.0%) | -$29.00 K(+1350.0%) |
| Mar 2014 | - | -$2000.00 | -$2000.00 |
| Dec 2013 | -$2000.00(<-9900.0%) | - | - |
| Dec 2012 | $0.00 | - | - |
FAQ
- What is Enlivex Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Enlivex Therapeutics?
- What is Enlivex Therapeutics annual CFI year-on-year change?
- What is Enlivex Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Enlivex Therapeutics?
- What is Enlivex Therapeutics quarterly CFI year-on-year change?
- What is Enlivex Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Enlivex Therapeutics?
- What is Enlivex Therapeutics TTM CFI year-on-year change?
What is Enlivex Therapeutics annual cash flow from investing activities?
The current annual CFI of ENLV is -$25.97 M
What is the all time high annual CFI for Enlivex Therapeutics?
Enlivex Therapeutics all-time high annual cash flow from investing activities is $62.52 M
What is Enlivex Therapeutics annual CFI year-on-year change?
Over the past year, ENLV annual cash flow from investing activities has changed by -$88.49 M (-141.53%)
What is Enlivex Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ENLV is -$794.00 K
What is the all time high quarterly CFI for Enlivex Therapeutics?
Enlivex Therapeutics all-time high quarterly cash flow from investing activities is $59.67 M
What is Enlivex Therapeutics quarterly CFI year-on-year change?
Over the past year, ENLV quarterly cash flow from investing activities has changed by -$4.74 M (-120.13%)
What is Enlivex Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ENLV is $12.38 M
What is the all time high TTM CFI for Enlivex Therapeutics?
Enlivex Therapeutics all-time high TTM cash flow from investing activities is $80.86 M
What is Enlivex Therapeutics TTM CFI year-on-year change?
Over the past year, ENLV TTM cash flow from investing activities has changed by +$45.36 M (+137.55%)